A. Ribas

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

A. Ribas, Axel Hauschild, Richard Kefford et al. · Journal of Clinical Oncology · 2008 · 156 citations

Medicine, Oncology, Pharmacology +17

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with <i>BRAF</i> V600E mutation-positive metastatic melanoma.

A. Ribas, K. B. Kim, Lynn M. Schuchter et al. · Journal of Clinical Oncology · 2011 · 132 citations

Medicine, Oncology, Pharmacology +14

1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

A. Ribas, Jason Chesney, Georgina V. Long et al. · Annals of Oncology · 2021 · 57 citations

Pharmacy, Oncology, Pharmacotherapy +14

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.

Joan Albanell, J Bellmunt, Raquel Molina et al. · PubMed · 1996 · 47 citations

Medicine, Oncology, Breast Oncology +12

Feasibility Trial of Methotrexate–Paclitaxel as a Second Line Therapy in Advanced Urothelial Cancer

J Bellmunt, J. Cos, Ramón Clèries et al. · Cancer Investigation · 2002 · 35 citations

Medicine, Oncology, Pharmacology +17